Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.47 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.47 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31092072 | 1.00 | PAOX (0.53) | PAOXSIGMAR1ALOX15GNAI3GNAO1 | |
| SCHEMBL3970460 | 1.00 | PAOX (0.53) | PAOXSIGMAR1ALOX15GNAI3GNAO1 | |
| SCHEMBL22564678 | 1.00 | PAOX (0.53) | PAOXSIGMAR1ALOX15GNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL20507343 | 0.98 | PAOX (0.52) | PAOXSIGMAR1ALOX15GNAI3GNAO1 | |
| SCHEMBL856408 | 0.98 | SIGMAR1 (0.50) | PAOXSIGMAR1ALOX15GNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL27751183 | 0.95 | SIGMAR1 (0.48) | PAOXSIGMAR1ALOX15GNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL3677133 | 0.95 | SIGMAR1 (0.48) | PAOXSIGMAR1ALOX15GNAI3GNAO1 | |
| SCHEMBL25344455 | 0.92 | HRH3 (0.48) | PAOXSIGMAR1ALOX15GNAI3GNAO1 | |
| SCHEMBL248151 | 0.90 | KEAP1 (0.56) | PAOXSIGMAR1ALOX15KEAP1SMN1; SMN2 | |
| SCHEMBL1615521 | 0.90 | ALOX15 (0.58) | SIGMAR1ALOX15KEAP1SMN1; SMN2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118652225-A | Phosphorus-free degradable CaSO (CaSOx resistance)4Small molecular scale inhibitor as well as preparation method and application thereof | 石家庄铁道大学 | 2024-09-17 | — | — | CN | disclosed |
| WO-2024140595-A1 | TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 珂阑(上海)医药科技有限公司 | 2024-07-04 | — | — | WO | disclosed |
| CN-118255685-A | Tricyclic compound, pharmaceutical composition and application thereof | 珂阑(上海)医药科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2023071601-A1 | DESLORATADINE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 天津市昕晨投资发展有限公司 | 2023-05-04 | — | — | WO | disclosed |
| CN-101827851-A | 5-cyano-thienopyridines for the treatment of tumors | MERCK PATENT GMBH | 2010-09-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | PLTP, LNPEP, PLIN3 | PAOX 1159/4885SIGMAR1 2858/4885ALOX15 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.